Your browser is no longer supported. Please, upgrade your browser.
ATHE Alterity Therapeutics Limited monthly Stock Chart
ATHE [NASD]
Alterity Therapeutics Limited
Index- P/E- EPS (ttm)-0.66 Insider Own18.70% Shs Outstand15.36M Perf Week-5.00%
Market Cap48.35M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float13.17M Perf Month10.14%
Income-9.90M PEG- EPS next Q- Inst Own4.30% Short Float0.41% Perf Quarter-38.96%
Sales- P/S- EPS this Y25.00% Inst Trans19.37% Short Ratio0.02 Perf Half Y155.94%
Book/sh0.34 P/B4.47 EPS next Y- ROA-92.10% Target Price- Perf Year54.22%
Cash/sh- P/C- EPS next 5Y- ROE-117.50% 52W Range0.28 - 5.15 Perf YTD94.87%
Dividend- P/FCF- EPS past 5Y-5.10% ROI- 52W High-70.49% Beta1.75
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low442.86% ATR0.25
Employees12 Current Ratio3.60 Sales Q/Q- Oper. Margin- RSI (14)47.38 Volatility6.17% 9.73%
OptionableNo Debt/Eq0.00 EPS Q/Q2.90% Profit Margin- Rel Volume0.19 Prev Close1.55
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.22M Price1.52
Recom- SMA201.95% SMA50-14.13% SMA20019.89% Volume413,893 Change-1.94%
Nov-16-20 10:42AM  
08:42AM  
Oct-26-20 10:03PM  
Aug-05-20 03:10PM  
Aug-04-20 09:07AM  
02:33AM  
Aug-03-20 09:33PM  
Jul-30-20 06:49PM  
Jul-01-20 08:12AM  
Jun-29-20 11:14PM  
May-20-20 08:58PM  
Apr-30-20 04:35AM  
Apr-21-20 05:50PM  
Feb-21-20 07:15PM  
Nov-11-19 10:30PM  
Sep-12-19 11:07PM  
Jul-29-19 08:00AM  
Jul-11-19 09:31PM  
May-06-19 08:00AM  
May-03-19 08:00AM  
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.